Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.46 |
| ▸ | EIF4E | P06730 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | MARS1 | P56192 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807852 | 0.83 | CNR1 (0.48) | CNR1EIF4ESRD5A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL3889534 | 0.82 | CNR1 (0.50) | CNR1EIF4ESRD5A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4805584 | 0.76 | CNR1 (0.48) | CNR1EIF4E | |
| SCHEMBL4505429 | 0.76 | DHODH (0.50) | CNR1EIF4ESRD5A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL15392431 | 0.73 | EIF4E (0.45) | CNR1EIF4ESRD5A2DHODHMARS1 | |
| SCHEMBL4807298 | 0.71 | CNR1 (0.54) | CNR1SRD5A2SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL4906770 | 0.71 | PTPN1 (0.47) | CNR1EIF4ESMN1; SMN2DHODHKDM4E | |
| SCHEMBL4515129 | 0.70 | HSD17B10 (0.58) | CNR1SMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL5358199 | 0.68 | CNR1 (0.70) | CNR1SRD5A2MARS1 | |
| SCHEMBL6498907 | 0.68 | ALDH1A1 (0.61) | EIF4ESRD5A2SMN1; SMN2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203699-A1 | AMINOMETHYLPYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS | 2009-08-13 | — | — | US | disclosed |
| EP-2010492-A2 | AMINOMETHYL PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007119001-A2 | AMINOMETHYL PYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203699-A1 | AMINOMETHYLPYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | TPMT, QDPR, HNMT | CNR1 987/4885EIF4E 2839/4885SRD5A2 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.